Global Circulating Tumor Cell Diagnostics Market Insights and Forecast to 2031

Report ID: 1197215 | Published Date: Jan 2025 | No. of Page: 125 | Base Year: 2024 | Rating: 4.5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Circulating Tumor Cell Diagnostics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 CTC Enrichment
        1.2.3 CTC Detection
        1.2.4 CTC Analysis
    1.3 Market by Application
        1.3.1 Global Circulating Tumor Cell Diagnostics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Tumorigenesis research
        1.3.3 EMT biomarkers development
        1.3.4 Cancer stem cell research
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Circulating Tumor Cell Diagnostics Market Perspective (2017-2028)
    2.2 Circulating Tumor Cell Diagnostics Growth Trends by Region
        2.2.1 Circulating Tumor Cell Diagnostics Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Circulating Tumor Cell Diagnostics Historic Market Size by Region (2017-2022)
        2.2.3 Circulating Tumor Cell Diagnostics Forecasted Market Size by Region (2023-2028)
    2.3 Circulating Tumor Cell Diagnostics Market Dynamics
        2.3.1 Circulating Tumor Cell Diagnostics Industry Trends
        2.3.2 Circulating Tumor Cell Diagnostics Market Drivers
        2.3.3 Circulating Tumor Cell Diagnostics Market Challenges
        2.3.4 Circulating Tumor Cell Diagnostics Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Circulating Tumor Cell Diagnostics Players by Revenue
        3.1.1 Global Top Circulating Tumor Cell Diagnostics Players by Revenue (2017-2022)
        3.1.2 Global Circulating Tumor Cell Diagnostics Revenue Market Share by Players (2017-2022)
    3.2 Global Circulating Tumor Cell Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Circulating Tumor Cell Diagnostics Revenue
    3.4 Global Circulating Tumor Cell Diagnostics Market Concentration Ratio
        3.4.1 Global Circulating Tumor Cell Diagnostics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor Cell Diagnostics Revenue in 2021
    3.5 Circulating Tumor Cell Diagnostics Key Players Head office and Area Served
    3.6 Key Players Circulating Tumor Cell Diagnostics Product Solution and Service
    3.7 Date of Enter into Circulating Tumor Cell Diagnostics Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumor Cell Diagnostics Breakdown Data by Type
    4.1 Global Circulating Tumor Cell Diagnostics Historic Market Size by Type (2017-2022)
    4.2 Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Type (2023-2028)
5 Circulating Tumor Cell Diagnostics Breakdown Data by Application
    5.1 Global Circulating Tumor Cell Diagnostics Historic Market Size by Application (2017-2022)
    5.2 Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Circulating Tumor Cell Diagnostics Market Size (2017-2028)
    6.2 North America Circulating Tumor Cell Diagnostics Market Size by Type
        6.2.1 North America Circulating Tumor Cell Diagnostics Market Size by Type (2017-2022)
        6.2.2 North America Circulating Tumor Cell Diagnostics Market Size by Type (2023-2028)
        6.2.3 North America Circulating Tumor Cell Diagnostics Market Share by Type (2017-2028)
    6.3 North America Circulating Tumor Cell Diagnostics Market Size by Application
        6.3.1 North America Circulating Tumor Cell Diagnostics Market Size by Application (2017-2022)
        6.3.2 North America Circulating Tumor Cell Diagnostics Market Size by Application (2023-2028)
        6.3.3 North America Circulating Tumor Cell Diagnostics Market Share by Application (2017-2028)
    6.4 North America Circulating Tumor Cell Diagnostics Market Size by Country
        6.4.1 North America Circulating Tumor Cell Diagnostics Market Size by Country (2017-2022)
        6.4.2 North America Circulating Tumor Cell Diagnostics Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Circulating Tumor Cell Diagnostics Market Size (2017-2028)
    7.2 Europe Circulating Tumor Cell Diagnostics Market Size by Type
        7.2.1 Europe Circulating Tumor Cell Diagnostics Market Size by Type (2017-2022)
        7.2.2 Europe Circulating Tumor Cell Diagnostics Market Size by Type (2023-2028)
        7.2.3 Europe Circulating Tumor Cell Diagnostics Market Share by Type (2017-2028)
    7.3 Europe Circulating Tumor Cell Diagnostics Market Size by Application
        7.3.1 Europe Circulating Tumor Cell Diagnostics Market Size by Application (2017-2022)
        7.3.2 Europe Circulating Tumor Cell Diagnostics Market Size by Application (2023-2028)
        7.3.3 Europe Circulating Tumor Cell Diagnostics Market Share by Application (2017-2028)
    7.4 Europe Circulating Tumor Cell Diagnostics Market Size by Country
        7.4.1 Europe Circulating Tumor Cell Diagnostics Market Size by Country (2017-2022)
        7.4.2 Europe Circulating Tumor Cell Diagnostics Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size (2017-2028)
    8.2 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Type
        8.2.1 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Circulating Tumor Cell Diagnostics Market Share by Type (2017-2028)
    8.3 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Application
        8.3.1 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Circulating Tumor Cell Diagnostics Market Share by Application (2017-2028)
    8.4 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Region
        8.4.1 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Circulating Tumor Cell Diagnostics Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Circulating Tumor Cell Diagnostics Market Size (2017-2028)
    9.2 Latin America Circulating Tumor Cell Diagnostics Market Size by Type
        9.2.1 Latin America Circulating Tumor Cell Diagnostics Market Size by Type (2017-2022)
        9.2.2 Latin America Circulating Tumor Cell Diagnostics Market Size by Type (2023-2028)
        9.2.3 Latin America Circulating Tumor Cell Diagnostics Market Share by Type (2017-2028)
    9.3 Latin America Circulating Tumor Cell Diagnostics Market Size by Application
        9.3.1 Latin America Circulating Tumor Cell Diagnostics Market Size by Application (2017-2022)
        9.3.2 Latin America Circulating Tumor Cell Diagnostics Market Size by Application (2023-2028)
        9.3.3 Latin America Circulating Tumor Cell Diagnostics Market Share by Application (2017-2028)
    9.4 Latin America Circulating Tumor Cell Diagnostics Market Size by Country
        9.4.1 Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2017-2022)
        9.4.2 Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size (2017-2028)
    10.2 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Type
        10.2.1 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Circulating Tumor Cell Diagnostics Market Share by Type (2017-2028)
    10.3 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Application
        10.3.1 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Circulating Tumor Cell Diagnostics Market Share by Application (2017-2028)
    10.4 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Country
        10.4.1 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Circulating Tumor Cell Diagnostics Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Janssen Diagnostics
        11.1.1 Janssen Diagnostics Company Details
        11.1.2 Janssen Diagnostics Business Overview
        11.1.3 Janssen Diagnostics Circulating Tumor Cell Diagnostics Introduction
        11.1.4 Janssen Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.1.5 Janssen Diagnostics Recent Developments
    11.2 Advanced Cell Diagnostics
        11.2.1 Advanced Cell Diagnostics Company Details
        11.2.2 Advanced Cell Diagnostics Business Overview
        11.2.3 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Introduction
        11.2.4 Advanced Cell Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.2.5 Advanced Cell Diagnostics Recent Developments
    11.3 Aviva Biosciences
        11.3.1 Aviva Biosciences Company Details
        11.3.2 Aviva Biosciences Business Overview
        11.3.3 Aviva Biosciences Circulating Tumor Cell Diagnostics Introduction
        11.3.4 Aviva Biosciences Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.3.5 Aviva Biosciences Recent Developments
    11.4 Biocept Inc
        11.4.1 Biocept Inc Company Details
        11.4.2 Biocept Inc Business Overview
        11.4.3 Biocept Inc Circulating Tumor Cell Diagnostics Introduction
        11.4.4 Biocept Inc Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.4.5 Biocept Inc Recent Developments
    11.5 Biofluidica Inc.
        11.5.1 Biofluidica Inc. Company Details
        11.5.2 Biofluidica Inc. Business Overview
        11.5.3 Biofluidica Inc. Circulating Tumor Cell Diagnostics Introduction
        11.5.4 Biofluidica Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.5.5 Biofluidica Inc. Recent Developments
    11.6 CellTraffix Inc.
        11.6.1 CellTraffix Inc. Company Details
        11.6.2 CellTraffix Inc. Business Overview
        11.6.3 CellTraffix Inc. Circulating Tumor Cell Diagnostics Introduction
        11.6.4 CellTraffix Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.6.5 CellTraffix Inc. Recent Developments
    11.7 Clearbridge BioMedics Pte Ltd
        11.7.1 Clearbridge BioMedics Pte Ltd Company Details
        11.7.2 Clearbridge BioMedics Pte Ltd Business Overview
        11.7.3 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Introduction
        11.7.4 Clearbridge BioMedics Pte Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.7.5 Clearbridge BioMedics Pte Ltd Recent Developments
    11.8 Epic Sciences Inc.
        11.8.1 Epic Sciences Inc. Company Details
        11.8.2 Epic Sciences Inc. Business Overview
        11.8.3 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Introduction
        11.8.4 Epic Sciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.8.5 Epic Sciences Inc. Recent Developments
    11.9 Fluxion Biosciences Inc.
        11.9.1 Fluxion Biosciences Inc. Company Details
        11.9.2 Fluxion Biosciences Inc. Business Overview
        11.9.3 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Introduction
        11.9.4 Fluxion Biosciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.9.5 Fluxion Biosciences Inc. Recent Developments
    11.10 ScreenCell
        11.10.1 ScreenCell Company Details
        11.10.2 ScreenCell Business Overview
        11.10.3 ScreenCell Circulating Tumor Cell Diagnostics Introduction
        11.10.4 ScreenCell Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.10.5 ScreenCell Recent Developments
    11.11 Silicon Biosystems
        11.11.1 Silicon Biosystems Company Details
        11.11.2 Silicon Biosystems Business Overview
        11.11.3 Silicon Biosystems Circulating Tumor Cell Diagnostics Introduction
        11.11.4 Silicon Biosystems Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.11.5 Silicon Biosystems Recent Developments
    11.12 Sysmex Corporation
        11.12.1 Sysmex Corporation Company Details
        11.12.2 Sysmex Corporation Business Overview
        11.12.3 Sysmex Corporation Circulating Tumor Cell Diagnostics Introduction
        11.12.4 Sysmex Corporation Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.12.5 Sysmex Corporation Recent Developments
    11.13 Greiner Bio-One GmbH
        11.13.1 Greiner Bio-One GmbH Company Details
        11.13.2 Greiner Bio-One GmbH Business Overview
        11.13.3 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Introduction
        11.13.4 Greiner Bio-One GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.13.5 Greiner Bio-One GmbH Recent Developments
    11.14 AdnaGen AG
        11.14.1 AdnaGen AG Company Details
        11.14.2 AdnaGen AG Business Overview
        11.14.3 AdnaGen AG Circulating Tumor Cell Diagnostics Introduction
        11.14.4 AdnaGen AG Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.14.5 AdnaGen AG Recent Developments
    11.15 Apocell Inc
        11.15.1 Apocell Inc Company Details
        11.15.2 Apocell Inc Business Overview
        11.15.3 Apocell Inc Circulating Tumor Cell Diagnostics Introduction
        11.15.4 Apocell Inc Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.15.5 Apocell Inc Recent Developments
    11.16 Biocep Ltd
        11.16.1 Biocep Ltd Company Details
        11.16.2 Biocep Ltd Business Overview
        11.16.3 Biocep Ltd Circulating Tumor Cell Diagnostics Introduction
        11.16.4 Biocep Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.16.5 Biocep Ltd Recent Developments
    11.17 Canopus Bioscience Ltd
        11.17.1 Canopus Bioscience Ltd Company Details
        11.17.2 Canopus Bioscience Ltd Business Overview
        11.17.3 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Introduction
        11.17.4 Canopus Bioscience Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.17.5 Canopus Bioscience Ltd Recent Developments
    11.18 Creatv Microtech Inc
        11.18.1 Creatv Microtech Inc Company Details
        11.18.2 Creatv Microtech Inc Business Overview
        11.18.3 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Introduction
        11.18.4 Creatv Microtech Inc Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.18.5 Creatv Microtech Inc Recent Developments
    11.19 Ikonisys Inc
        11.19.1 Ikonisys Inc Company Details
        11.19.2 Ikonisys Inc Business Overview
        11.19.3 Ikonisys Inc Circulating Tumor Cell Diagnostics Introduction
        11.19.4 Ikonisys Inc Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.19.5 Ikonisys Inc Recent Developments
    11.20 IV Diagnostics Inc
        11.20.1 IV Diagnostics Inc Company Details
        11.20.2 IV Diagnostics Inc Business Overview
        11.20.3 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Introduction
        11.20.4 IV Diagnostics Inc Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.20.5 IV Diagnostics Inc Recent Developments
    11.21 Miltenyi Biotech GmbH
        11.21.1 Miltenyi Biotech GmbH Company Details
        11.21.2 Miltenyi Biotech GmbH Business Overview
        11.21.3 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Introduction
        11.21.4 Miltenyi Biotech GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.21.5 Miltenyi Biotech GmbH Recent Developments
    11.22 Nanostring Technologies Inc
        11.22.1 Nanostring Technologies Inc Company Details
        11.22.2 Nanostring Technologies Inc Business Overview
        11.22.3 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Introduction
        11.22.4 Nanostring Technologies Inc Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.22.5 Nanostring Technologies Inc Recent Developments
    11.23 Rarecells Diagnostics.
        11.23.1 Rarecells Diagnostics. Company Details
        11.23.2 Rarecells Diagnostics. Business Overview
        11.23.3 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Introduction
        11.23.4 Rarecells Diagnostics. Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.23.5 Rarecells Diagnostics. Recent Developments
    11.24 Vitatex Inc
        11.24.1 Vitatex Inc Company Details
        11.24.2 Vitatex Inc Business Overview
        11.24.3 Vitatex Inc Circulating Tumor Cell Diagnostics Introduction
        11.24.4 Vitatex Inc Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022)
        11.24.5 Vitatex Inc Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer

List of Tables
    Table 1. Global Circulating Tumor Cell Diagnostics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of CTC Enrichment
    Table 3. Key Players of CTC Detection
    Table 4. Key Players of CTC Analysis
    Table 5. Global Circulating Tumor Cell Diagnostics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 6. Global Circulating Tumor Cell Diagnostics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Circulating Tumor Cell Diagnostics Market Size by Region (2017-2022) & (US$ Million)
    Table 8. Global Circulating Tumor Cell Diagnostics Market Share by Region (2017-2022)
    Table 9. Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 10. Global Circulating Tumor Cell Diagnostics Market Share by Region (2023-2028)
    Table 11. Circulating Tumor Cell Diagnostics Market Trends
    Table 12. Circulating Tumor Cell Diagnostics Market Drivers
    Table 13. Circulating Tumor Cell Diagnostics Market Challenges
    Table 14. Circulating Tumor Cell Diagnostics Market Restraints
    Table 15. Global Circulating Tumor Cell Diagnostics Revenue by Players (2017-2022) & (US$ Million)
    Table 16. Global Circulating Tumor Cell Diagnostics Revenue Share by Players (2017-2022)
    Table 17. Global Top Circulating Tumor Cell Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cell Diagnostics as of 2021)
    Table 18. Ranking of Global Top Circulating Tumor Cell Diagnostics Companies by Revenue (US$ Million) in 2021
    Table 19. Global 5 Largest Players Market Share by Circulating Tumor Cell Diagnostics Revenue (CR5 and HHI) & (2017-2022)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Circulating Tumor Cell Diagnostics Product Solution and Service
    Table 22. Date of Enter into Circulating Tumor Cell Diagnostics Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Circulating Tumor Cell Diagnostics Market Size by Type (2017-2022) & (US$ Million)
    Table 25. Global Circulating Tumor Cell Diagnostics Revenue Market Share by Type (2017-2022)
    Table 26. Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 27. Global Circulating Tumor Cell Diagnostics Revenue Market Share by Type (2023-2028)
    Table 28. Global Circulating Tumor Cell Diagnostics Market Size by Application (2017-2022) & (US$ Million)
    Table 29. Global Circulating Tumor Cell Diagnostics Revenue Share by Application (2017-2022)
    Table 30. Global Circulating Tumor Cell Diagnostics Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 31. Global Circulating Tumor Cell Diagnostics Revenue Share by Application (2023-2028)
    Table 32. North America Circulating Tumor Cell Diagnostics Market Size by Type (2017-2022) & (US$ Million)
    Table 33. North America Circulating Tumor Cell Diagnostics Market Size by Type (2023-2028) & (US$ Million)
    Table 34. North America Circulating Tumor Cell Diagnostics Market Size by Application (2017-2022) & (US$ Million)
    Table 35. North America Circulating Tumor Cell Diagnostics Market Size by Application (2023-2028) & (US$ Million)
    Table 36. North America Circulating Tumor Cell Diagnostics Market Size by Country (2017-2022) & (US$ Million)
    Table 37. North America Circulating Tumor Cell Diagnostics Market Size by Country (2023-2028) & (US$ Million)
    Table 38. Europe Circulating Tumor Cell Diagnostics Market Size by Type (2017-2022) & (US$ Million)
    Table 39. Europe Circulating Tumor Cell Diagnostics Market Size by Type (2023-2028) & (US$ Million)
    Table 40. Europe Circulating Tumor Cell Diagnostics Market Size by Application (2017-2022) & (US$ Million)
    Table 41. Europe Circulating Tumor Cell Diagnostics Market Size by Application (2023-2028) & (US$ Million)
    Table 42. Europe Circulating Tumor Cell Diagnostics Market Size by Country (2017-2022) & (US$ Million)
    Table 43. Europe Circulating Tumor Cell Diagnostics Market Size by Country (2023-2028) & (US$ Million)
    Table 44. Asia Pacific Circulating Tumor Cell Diagnostics Market Size by Type (2017-2022) & (US$ Million)
    Table 45. Asia Pacific Circulating Tumor Cell Diagnostics Market Size by Type (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Circulating Tumor Cell Diagnostics Market Size by Application (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Circulating Tumor Cell Diagnostics Market Size by Application (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Circulating Tumor Cell Diagnostics Market Size by Region (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Circulating Tumor Cell Diagnostics Market Size by Region (2023-2028) & (US$ Million)
    Table 50. Latin America Circulating Tumor Cell Diagnostics Market Size by Type (2017-2022) & (US$ Million)
    Table 51. Latin America Circulating Tumor Cell Diagnostics Market Size by Type (2023-2028) & (US$ Million)
    Table 52. Latin America Circulating Tumor Cell Diagnostics Market Size by Application (2017-2022) & (US$ Million)
    Table 53. Latin America Circulating Tumor Cell Diagnostics Market Size by Application (2023-2028) & (US$ Million)
    Table 54. Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2017-2022) & (US$ Million)
    Table 55. Latin America Circulating Tumor Cell Diagnostics Market Size by Country (2023-2028) & (US$ Million)
    Table 56. Middle East and Africa Circulating Tumor Cell Diagnostics Market Size by Type (2017-2022) & (US$ Million)
    Table 57. Middle East and Africa Circulating Tumor Cell Diagnostics Market Size by Type (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Circulating Tumor Cell Diagnostics Market Size by Application (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Circulating Tumor Cell Diagnostics Market Size by Application (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Circulating Tumor Cell Diagnostics Market Size by Country (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Circulating Tumor Cell Diagnostics Market Size by Country (2023-2028) & (US$ Million)
    Table 62. Janssen Diagnostics Company Details
    Table 63. Janssen Diagnostics Business Overview
    Table 64. Janssen Diagnostics Circulating Tumor Cell Diagnostics Product
    Table 65. Janssen Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 66. Janssen Diagnostics Recent Developments
    Table 67. Advanced Cell Diagnostics Company Details
    Table 68. Advanced Cell Diagnostics Business Overview
    Table 69. Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Product
    Table 70. Advanced Cell Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 71. Advanced Cell Diagnostics Recent Developments
    Table 72. Aviva Biosciences Company Details
    Table 73. Aviva Biosciences Business Overview
    Table 74. Aviva Biosciences Circulating Tumor Cell Diagnostics Product
    Table 75. Aviva Biosciences Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 76. Aviva Biosciences Recent Developments
    Table 77. Biocept Inc Company Details
    Table 78. Biocept Inc Business Overview
    Table 79. Biocept Inc Circulating Tumor Cell Diagnostics Product
    Table 80. Biocept Inc Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 81. Biocept Inc Recent Developments
    Table 82. Biofluidica Inc. Company Details
    Table 83. Biofluidica Inc. Business Overview
    Table 84. Biofluidica Inc. Circulating Tumor Cell Diagnostics Product
    Table 85. Biofluidica Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 86. Biofluidica Inc. Recent Developments
    Table 87. CellTraffix Inc. Company Details
    Table 88. CellTraffix Inc. Business Overview
    Table 89. CellTraffix Inc. Circulating Tumor Cell Diagnostics Product
    Table 90. CellTraffix Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 91. CellTraffix Inc. Recent Developments
    Table 92. Clearbridge BioMedics Pte Ltd Company Details
    Table 93. Clearbridge BioMedics Pte Ltd Business Overview
    Table 94. Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Product
    Table 95. Clearbridge BioMedics Pte Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 96. Clearbridge BioMedics Pte Ltd Recent Developments
    Table 97. Epic Sciences Inc. Company Details
    Table 98. Epic Sciences Inc. Business Overview
    Table 99. Epic Sciences Inc. Circulating Tumor Cell Diagnostics Product
    Table 100. Epic Sciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 101. Epic Sciences Inc. Recent Developments
    Table 102. Fluxion Biosciences Inc. Company Details
    Table 103. Fluxion Biosciences Inc. Business Overview
    Table 104. Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Product
    Table 105. Fluxion Biosciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 106. Fluxion Biosciences Inc. Recent Developments
    Table 107. ScreenCell Company Details
    Table 108. ScreenCell Business Overview
    Table 109. ScreenCell Circulating Tumor Cell Diagnostics Product
    Table 110. ScreenCell Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 111. ScreenCell Recent Developments
    Table 112. Silicon Biosystems Company Details
    Table 113. Silicon Biosystems Business Overview
    Table 114. Silicon Biosystems Circulating Tumor Cell Diagnostics Product
    Table 115. Silicon Biosystems Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 116. Silicon Biosystems Recent Developments
    Table 117. Sysmex Corporation Company Details
    Table 118. Sysmex Corporation Business Overview
    Table 119. Sysmex Corporation Circulating Tumor Cell Diagnostics Product
    Table 120. Sysmex Corporation Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 121. Sysmex Corporation Recent Developments
    Table 122. Greiner Bio-One GmbH Company Details
    Table 123. Greiner Bio-One GmbH Business Overview
    Table 124. Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Product
    Table 125. Greiner Bio-One GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 126. Greiner Bio-One GmbH Recent Developments
    Table 127. AdnaGen AG Company Details
    Table 128. AdnaGen AG Business Overview
    Table 129. AdnaGen AG Circulating Tumor Cell Diagnostics Product
    Table 130. AdnaGen AG Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 131. AdnaGen AG Recent Developments
    Table 132. Apocell Inc Company Details
    Table 133. Apocell Inc Business Overview
    Table 134. Apocell Inc Circulating Tumor Cell Diagnostics Product
    Table 135. Apocell Inc Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 136. Apocell Inc Recent Developments
    Table 137. Biocep Ltd Company Details
    Table 138. Biocep Ltd Business Overview
    Table 139. Biocep Ltd Circulating Tumor Cell Diagnostics Product
    Table 140. Biocep Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 141. Biocep Ltd Recent Developments
    Table 142. Canopus Bioscience Ltd Company Details
    Table 143. Canopus Bioscience Ltd Business Overview
    Table 144. Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Product
    Table 145. Canopus Bioscience Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 146. Canopus Bioscience Ltd Recent Developments
    Table 147. Creatv Microtech Inc Company Details
    Table 148. Creatv Microtech Inc Business Overview
    Table 149. Creatv Microtech Inc Circulating Tumor Cell Diagnostics Product
    Table 150. Creatv Microtech Inc Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 151. Creatv Microtech Inc Recent Developments
    Table 152. Ikonisys Inc Company Details
    Table 153. Ikonisys Inc Business Overview
    Table 154. Ikonisys Inc Circulating Tumor Cell Diagnostics Product
    Table 155. Ikonisys Inc Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 156. Ikonisys Inc Recent Developments
    Table 157. IV Diagnostics Inc Company Details
    Table 158. IV Diagnostics Inc Business Overview
    Table 159. IV Diagnostics Inc Circulating Tumor Cell Diagnostics Product
    Table 160. IV Diagnostics Inc Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 161. IV Diagnostics Inc Recent Developments
    Table 162. Miltenyi Biotech GmbH Company Details
    Table 163. Miltenyi Biotech GmbH Business Overview
    Table 164. Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Product
    Table 165. Miltenyi Biotech GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 166. Miltenyi Biotech GmbH Recent Developments
    Table 167. Nanostring Technologies Inc Company Details
    Table 168. Nanostring Technologies Inc Business Overview
    Table 169. Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Product
    Table 170. Nanostring Technologies Inc Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 171. Nanostring Technologies Inc Recent Developments
    Table 172. Rarecells Diagnostics. Company Details
    Table 173. Rarecells Diagnostics. Business Overview
    Table 174. Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Product
    Table 175. Rarecells Diagnostics. Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 176. Rarecells Diagnostics. Recent Developments
    Table 177. Vitatex Inc Company Details
    Table 178. Vitatex Inc Business Overview
    Table 179. Vitatex Inc Circulating Tumor Cell Diagnostics Product
    Table 180. Vitatex Inc Revenue in Circulating Tumor Cell Diagnostics Business (2017-2022) & (US$ Million)
    Table 181. Vitatex Inc Recent Developments
    Table 182. Research Programs/Design for This Report
    Table 183. Key Data Information from Secondary Sources
    Table 184. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Circulating Tumor Cell Diagnostics Market Share by Type: 2021 VS 2028
    Figure 2. CTC Enrichment Features
    Figure 3. CTC Detection Features
    Figure 4. CTC Analysis Features
    Figure 5. Global Circulating Tumor Cell Diagnostics Market Share by Application: 2021 VS 2028
    Figure 6. Tumorigenesis research Case Studies
    Figure 7. EMT biomarkers development Case Studies
    Figure 8. Cancer stem cell research Case Studies
    Figure 9. Others Case Studies
    Figure 10. Circulating Tumor Cell Diagnostics Report Years Considered
    Figure 11. Global Circulating Tumor Cell Diagnostics Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 12. Global Circulating Tumor Cell Diagnostics Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 13. Global Circulating Tumor Cell Diagnostics Market Share by Region: 2021 VS 2028
    Figure 14. Global Circulating Tumor Cell Diagnostics Market Share by Players in 2021
    Figure 15. Global Top Circulating Tumor Cell Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cell Diagnostics as of 2021)
    Figure 16. The Top 10 and 5 Players Market Share by Circulating Tumor Cell Diagnostics Revenue in 2021
    Figure 17. North America Circulating Tumor Cell Diagnostics Market Size YoY (2017-2028) & (US$ Million)
    Figure 18. North America Circulating Tumor Cell Diagnostics Market Size Market Share by Type (2017-2028)
    Figure 19. North America Circulating Tumor Cell Diagnostics Market Size Market Share by Application (2017-2028)
    Figure 20. North America Circulating Tumor Cell Diagnostics Market Size Share by Country (2017-2028)
    Figure 21. United States Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Canada Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Europe Circulating Tumor Cell Diagnostics Market Size YoY (2017-2028) & (US$ Million)
    Figure 24. Europe Circulating Tumor Cell Diagnostics Market Size Market Share by Type (2017-2028)
    Figure 25. Europe Circulating Tumor Cell Diagnostics Market Size Market Share by Application (2017-2028)
    Figure 26. Europe Circulating Tumor Cell Diagnostics Market Size Share by Country (2017-2028)
    Figure 27. Germany Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. France Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. U.K. Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Italy Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Russia Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Nordic Countries Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Asia-Pacific Circulating Tumor Cell Diagnostics Market Size YoY (2017-2028) & (US$ Million)
    Figure 34. Asia Pacific Circulating Tumor Cell Diagnostics Market Size Market Share by Type (2017-2028)
    Figure 35. Asia Pacific Circulating Tumor Cell Diagnostics Market Size Market Share by Application (2017-2028)
    Figure 36. Asia Pacific Circulating Tumor Cell Diagnostics Market Size Share by Region (2017-2028)
    Figure 37. China Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Japan Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. South Korea Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Southeast Asia Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. India Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Australia Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Latin America Circulating Tumor Cell Diagnostics Market Size YoY (2017-2028) & (US$ Million)
    Figure 44. Latin America Circulating Tumor Cell Diagnostics Market Size Market Share by Type (2017-2028)
    Figure 45. Latin America Circulating Tumor Cell Diagnostics Market Size Market Share by Application (2017-2028)
    Figure 46. Latin America Circulating Tumor Cell Diagnostics Market Size Share by Country (2017-2028)
    Figure 47. Mexico Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 48. Brazil Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 49. Middle East & Africa Circulating Tumor Cell Diagnostics Market Size YoY (2017-2028) & (US$ Million)
    Figure 50. Middle East and Africa Circulating Tumor Cell Diagnostics Market Size Market Share by Type (2017-2028)
    Figure 51. Middle East and Africa Circulating Tumor Cell Diagnostics Market Size Market Share by Application (2017-2028)
    Figure 52. Middle East and Africa Circulating Tumor Cell Diagnostics Market Size Share by Country (2017-2028)
    Figure 53. Turkey Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 54. Saudi Arabia Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. UAE Circulating Tumor Cell Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 56. Janssen Diagnostics Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 57. Advanced Cell Diagnostics Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 58. Aviva Biosciences Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 59. Biocept Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 60. Biofluidica Inc. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 61. CellTraffix Inc. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 62. Clearbridge BioMedics Pte Ltd Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 63. Epic Sciences Inc. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 64. Fluxion Biosciences Inc. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 65. ScreenCell Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 66. Silicon Biosystems Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 67. Sysmex Corporation Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 68. Greiner Bio-One GmbH Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 69. AdnaGen AG Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 70. Apocell Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 71. Biocep Ltd Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 72. Canopus Bioscience Ltd Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 73. Creatv Microtech Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 74. Ikonisys Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 75. IV Diagnostics Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 76. Miltenyi Biotech GmbH Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 77. Nanostring Technologies Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 78. Rarecells Diagnostics. Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 79. Vitatex Inc Revenue Growth Rate in Circulating Tumor Cell Diagnostics Business (2017-2022)
    Figure 80. Bottom-up and Top-down Approaches for This Report
    Figure 81. Data Triangulation
    Figure 82. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
Frequently Asked Questions
Circulating Tumor Cell Diagnostics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Circulating Tumor Cell Diagnostics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Circulating Tumor Cell Diagnostics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports